SNUS Sonus Pharmaceuticals (MM)

Sonus Pharmaceuticals, Inc. (NASDAQ:SNUS) today announced that it will release first quarter financial results on Wednesday, May 9, at the close of market and hold a conference call at 1:30 P.M. PT/4:30 P.M. ET. The first quarter conference call will be broadcast live and can be accessed on the Sonus web site at www.sonuspharma.com/events.html. The call will be archived at the same link. A telephone replay of the call will be available from May 9, 4:30 P.M. PT/7:30 P.M. ET, for one week at 800-405-2236 or 303-590-3000 for international calls; Conference ID: 11088543. About Sonus Pharmaceuticals, Inc. Located near Seattle, Washington, Sonus Pharmaceuticals is focused on the development of cancer drugs that are designed to provide better efficacy, safety and tolerability, and are more convenient to use. The Company�s lead product candidate, TOCOSOL� Paclitaxel, is currently in a Phase 3 pivotal trial for the potential treatment of metastatic breast cancer. TOCOSOL Paclitaxel is a vitamin E-based emulsion formulation of paclitaxel that may have the ability to reduce treatment-limiting side effects and improve anti-tumor activity. Compared to currently marketed taxane products, TOCOSOL Paclitaxel allows for shorter infusion times and does not require any time-consuming preparation prior to administration. In addition to the continuing development of TOCOSOL Paclitaxel, Sonus initiated a Phase 1 clinical study for its second cancer drug, TOCOSOL Camptothecin, in September 2006. For additional information on Sonus, including past news releases, please visit www.sonuspharma.com. Safe Harbor Certain statements made in this press release are forward-looking such as those, among others, relating to the development, safety and efficacy of therapeutic drugs and potential applications for these products. As discussed in Sonus Pharmaceuticals� filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for 2006, actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others:�the Company�s products will require extensive clinical testing and approval by regulatory authorities; such approvals are lengthy and expensive and may never occur; risks that the Company will not be able to complete the Phase 3 clinical trial for TOCOSOL Paclitaxel; risks that clinical studies with TOCOSOL Paclitaxel will be delayed or will not be successful; risks that the FDA may not approve the TOCOSOL Paclitaxel New Drug Application; risks that the Phase 1 clinical trial for TOCOSOL Camptothecin will not be successful; risks of successful development of therapeutic drugs; and risks that the Company may not be successful in obtaining funding from third parties or completing a financing necessary to support the costs and expenses of clinical studies as well as research and development activities. The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof.